Back to Search
Start Over
Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
- Source :
- Open Forum Infectious Diseases, Open Forum Infectious Diseases, 2015, 2 (4), pp.ofv175. ⟨10.1093/ofid/ofv175⟩, Open Forum Infectious Diseases, Oxford University Press, 2015, 2 (4), pp.ofv175. ⟨10.1093/ofid/ofv175⟩
- Publication Year :
- 2015
- Publisher :
- Oxford University Press, 2015.
-
Abstract
- Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs.
- Subjects :
- medicine.medical_specialty
Tuberculosis
Side effect
linezolid
Antituberculous drugs
Pharmacology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Starter
Internal medicine
ethionamide
medicine
030212 general & internal medicine
0303 health sciences
030306 microbiology
business.industry
medicine.disease
multidrug-resistant tuberculosis
[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
3. Good health
Multiple drug resistance
Infectious Diseases
Oncology
chemistry
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
Linezolid
[SDV.IMM]Life Sciences [q-bio]/Immunology
Ethionamide
Brief Reports
neuropathy
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 23288957
- Volume :
- 2
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Open Forum Infectious Diseases
- Accession number :
- edsair.doi.dedup.....09d51e3e2b5680eee6be8248d344d7b7